by MM360 Staff Writer | Oct 1, 2020 | Featured News, Myeloma News
House Oversight Committee hold hearings on drug Pricing. The Committee is holding two days of hearings with top executives of major drug companies to examine their pricing practices for some of the costliest drugs in the United States. The hearings, titled...
by MM360 Staff Writer | Sep 28, 2020 | Featured News, Myeloma News
ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the B-cell maturation antigen (sBCMA) protein to monitor people with blood cancers, including multiple myeloma. Serum B-cell maturation...
by MM360 Staff Writer | Sep 22, 2020 | Featured News, Myeloma News
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma Bristol Myers Squibb and bluebird bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...
by MM360 Staff Writer | Feb 28, 2018 | Featured News, Myeloma News
A Swedish study published in Haematologica suggests that infections are a major cause of morbidity and mortality in patients with multiple myeloma. The population-based study of 9253 patients showed that infection caused 22% of deaths in patients diagnosed...
